纳米颗粒在治疗糖尿病并发症中的作用:一项全面研究
Siddharth Satpathy1, Lipsa Leena Panigrahi1, Manoranjan Arakha1
1Centre for Biotechnology, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, 751003, Odisha, India.
Current topics in medicinal chemistry
|April 1, 2024
概括
糖尿病对全球健康和经济构成挑战. 纳米结构材料,如纳米粒子 (SeNPs),在治疗糖尿病及其并发症方面表现有前途,提供了一种新的治疗方法.
科学领域:
- 生物医学科学 生物医学科学
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
背景情况:
- 糖尿病是一种日益严重的全球流行病,对医疗保健和经济产生重大影响.
- 生活方式因素有助于胰岛素抵抗,胰腺β细胞损伤和与糖尿病相关的并发症.
- 传统的糖尿病管理在预防并发症方面面临争议.
研究的目的:
- 审查1型和2型糖尿病的病理生理学,诊断和治疗方法.
- 检查糖尿病病 (DN) 作为1型糖尿病并发症的案例研究.
- 突出糖尿病的经济负担,并探索纳米结构材料 (NSM) 作为新型治疗剂.
主要方法:
- 关于糖尿病病理生理学和管理的综合文献综述.
- 分析传统治疗策略及其局限性.
- 研究纳米结构材料的作用和有效性,特别是纳米粒子 (SeNPs).
主要成果:
- 糖尿病的管理是复杂的,关于预防并发症的持续辩论.
- 纳米结构材料,包括SeNPs,在糖尿病治疗中显示出潜力.
- 糖尿病病是糖尿病相关并发症的一个重要例子.
结论:
- 糖尿病带来了多方面的挑战,包括经济和医疗负担.
- 传统治疗有局限性,需要探索替代疗法.
- 纳米粒子 (SeNPs) 代表了用于新型糖尿病管理策略的有希望的纳米结构材料.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Diabetes: Management and Pharmacotherapy
277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
530
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
530
Oral Hypoglycemic Agents: Sulfonylureas
207
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
207


